trending Market Intelligence /marketintelligence/en/news-insights/trending/f6WOXLokPGS0qxC61FwlRQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Chinese drug developer Allist Pharmaceuticals gets 1.18B yuan in financing

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Banking Essentials Newsletter: May Edition

Blog

Global M&A Infographic Q1 2021


Chinese drug developer Allist Pharmaceuticals gets 1.18B yuan in financing

Healthcare-focused private equity firm Shiyu Capital, also known as Shenzhen Shiyu Investment Management, led a 1.18 billion yuan series A funding round for Chinese drug developer Allist Pharmaceuticals Inc., DealStreetAsia reported, citing a company announcement.

Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment Management Ltd. also supported the company, which focuses on the fields of cardiovascular, acid-related diseases and cancers, according to the report.

Allist will use the proceeds for drug research and for advancing product commercialization and foreign cooperation, the report noted.

As of May 24, US$1 was equivalent to 6.90 Chinese yuan.